Apyx Medical Corp (APYX): Results of Operations and Financial Condition
Apyx Medical Corp (APYX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_970692.htm EXHIBIT 99.1 ex_970692.htm EXHIBIT 99.1 Apyx Medical Corporation Reports Second Quarter 2026 Financial Results • Reported total revenue of $13.9 million in the second quarter of 2026 primarily driven by 28% growth in the Surgical Aesthetics segment • Succe
How this was made
The 30-second read
Why it matters
Traders can update near-term expectations based on the disclosed Q2 revenue, segment mix shift, cash position, and the expanded FDA 510(k) clearance that enables a limited commercial launch of AYON power liposuction handpieces. Reaffirmed FY2026 revenue guidance provides a direct anchor for modeling.
Market read
The filing combines a fresh quarterly print with a regulatory expansion and a guidance reaffirmation, creating a tradable catalyst set for APYX around the scheduled call.
What to watch
OEM revenue declined 12% and management expects continued OEM pressure; tariffs also affected gross margin, which could cap upside if costs persist.
Background
This SEC 8-K includes Exhibit 99.1 with Apyx’s Q2 2026 financial results and operating highlights for its Surgical Aesthetics business (Renuvion and AYON).
Ticker impact
Apyx reported Q2 2026 revenue of $13.9M, Surgical Aesthetics growth of 28%, and reaffirmed FY2026 guidance of $59.0M to $60.0M.
Likely positive bias for the stock into/after the 4:30 p.m. ET call, with upside contingent on follow-through in AYON uptake and margin trajectory.
The filing discloses multiple decision-relevant datapoints: revenue beat vs prior-year, segment growth mix shift, cash runway through 2027, and a specific regulatory expansion enabling a limited commercial launch.
Market effects
Supports demand narrative for surgical aesthetics platforms and procedure-adjacent device adoption, potentially improving sentiment toward small-cap medtech with regulatory momentum.
No specific regional market impact beyond U.S. commercial rollout commentary.
International Surgical Aesthetics generator and handpiece sales contributed to growth, but the disclosure is company-specific rather than a global sector shock.
Counterpoint
Despite revenue growth, APYX still reported a net loss and higher operating cash burn, so the market may discount the guidance reaffirmation until profitability improves.
Key entities
- companyApyx Medical Corporation
NASDAQ-listed surgical aesthetics company reporting Q2 2026 results and reaffirming FY2026 revenue guidance.
- productAYON Body Contouring System
Platform receiving expanded FDA 510(k) clearance to include power liposuction and starting a limited commercial launch.
- productRenuvion
Surgical aesthetics technology referenced in clinical data and used in combination treatments.
